Kunyange zvazvo pane, ikozvino, hapana mushonga wekutsamwisa bhood syndrome (IBS), kune marudzi mazhinji emishonga anowanikwa izvo zvinotarirwa zviratidzo zveBS . Vamwe vavo vanongotaura nezvechiratidzo chekudya, asi mishonga mitsva iri kuuya kumusika iyo yakagadzirirwa kutarisa zvakananga kusagadzikana kwese kunoenderana neBS.
Izvi ndizvo zvinoshandiswa kunyanya kushandisa mishonga inoshandiswa kurapa munhu ane IBS.
Yeuka kuti haisi mishonga yose inogona kunge yakanaka kwauri. Imishonga ipi iyo chiremba wako achakurudzira, kana iripo, inobva pane zvakaitika munyaya yezvechiremba, kuoma kwezviratidzo zvako, uye chinetso chako chinonyanya kukura. Mimwe yemishonga iyi inowanikwa nemishonga yega, asi dzimwe dzakawanikwa pane-the-counter. Ramba uchiyeuka kuti nemhaka yokuti chimwe chinhu chiripo pasina chiremba hazvirevi kuti chakakodzera kwauri. Iva nechokwadi chekuwana chibvumirano chechiremba wako usati waedza chimwe chinhu chitsva.
Gwaro Guru IBS Mishonga Options
Mhando dzemhando dzinotevera dzemishonga dzinogona kurongerwa kune ani zvake ari kutarisana neBS, pasinei nehuwandu hwavo hwakasiyana . (Ramba uchiverenga kuti uwane ruzivo nezvemishonga inonyanya kurwisa mararamiro-anonyanya kuve IBS (IBS-D) uye kubatwa-zvakanyanya IBS (IBS-C).
Antispasmodic Mishonga
Mishonga inonzi Antispasmodic inowanzotarisirwa kuBS, sezvo inogona kubatsira kubvisa marwadzo emimba nekupwanya izvo zvakakosha kuva neBS.
Zvisinei, ivo vanowanzova nehutano hwekudzivirira uye, saka, vangasava sarudzo yakanakisisa kune munhu ane IBS-C. Sezvo kutsvakurudza pamusoro pekuchengetedzwa kwemaantispasmodics kwekushandisa kwenguva refu ishoma, mishonga iyi inogona kuva yakakodzerwa nekushandiswa kwenguva pfupi bedzi. Antispasmodics dzakajairika dzakanyorerwa IBS dzinosanganisira:
- Bentyl (dicyclomine)
- Buscopan (hyoscine butylbromide)
- Anaspaz, Cystospaz, Levbid, Levsin (hyoscamine)
- Mebeverine (isina kuwanikwa muUnited States)
Antidepressants
Zvinodzvinyirira zvinowanzoshandiswa pamadhodhodho akaderera senzira yekurapa zviratidzo zveBS sezvo vane marwadzo-kununura maitiro uye vakachengeteka kwenguva refu. Chiremba wako anogona kukurudzira anodzvinyirirwa kunyange kana iwe usina kuora mwoyo. Kana iwe uine kuora mwoyo kana kufunganya pamwe chete neBHS yako, zvinowanzoita kuti chiremba wako asarudze sarudzo iyi.
Mukuwedzera pakubvisa marwadzo, vanodzvinyirira dzimwe nguva vanove nemigumisiro inosanganisa kudya. Nokudaro, chiremba wako angaita sarudzo yavo zvichienderana kana iwe une IBS-C kana IBS-D. Mitero inowanikwa inosanganisira yekare tricyclic antidepressants (zviri nani kune IBS-D) kana zvimwe zvezvitsva zvitsva zvakadai sedotonin reuptake inhibitors (SSRIs) serotonin-norepinephrine reuptake inhibitors, zvose zvingasimudzira IBS-C.
Mishonga Inoshandiswa Pakudhairha-Predominant IBS
Dare rekare rekudzivirira chirwere ichi rinoramba riri Imodium (loperamide), iro rinowanika pane-the-counter. Zvisinei, mishonga miviri yemishonga yakagadziriswa ichangobva kugamuchira mvumo yeDAA yekurapa IBS-D:
Xifaxan (rifaximin) chirwere chinorwisa mabhakitiriya chakatanga kushandiswa kurapa chirwere chevaya vanofambisa uye mabhakitiriya maduku emukati akawandisa (SIBO).
FDA inogamuchirwa ndeyekurapa kwe "kusina kuvimbiswa IBS." Xifaxan inoshanda zvakasiyana nekuwanda kwemishonga inorwisa mabhakitiriya sezvo isingapinde muropa rako asi asi inowanika kuisa mabhakitiriya mumatumbo ako maduku uye makuru. Inofungidzirwa kuti yakachengeteka kushandiswa kusvika pamatatu matatu emavhiki maviri.
Viberzi (eluxadoline) mishonga inobata maopioid receptors muzvokudya zvako kuti udzivise zviratidzo zvekurwadziwa kwepamuviri uye kurwara kwevanhu vane chirwere-chinonyanya kukosha IBS (IBS-D). Nokuti Viberzi mishonga inoputika, iyo inorondedzerwa sechinhu chinodzora uye kune zvimwe zvinetso pamusoro pekugona kukanganisa.
Mishonga Inoshandiswa Pakudzivirira Predominant IBS
Mavara emarudzi ose anowanzoshandiswa kugadzirisa zviratidzo zvekudzivirirwa. Miralax (polyethylene glycol), iyo isingadizve chiremba, ndiyo chete inodzidzwa nevatsvakurudzi kubudirira kwayo mukuderedza zviratidzo zveBS. Chimwe chekudzidza chakawana kuti chaibatsira pakudzikisa kuvimbiswa nekugadzirisa zvigaro, asi kwete kubvisa marwadzo eBS.
Ikozvino pane zvishomanana zvishandiso zvemishonga mishonga yekurapa IBS-C:
Linzess (linaclotide) inoshanda pane zvinokwana mukati megumbo rekudya kuti uwedzere huwandu hwemvura mumatumbo ako makuru. Mukuwedzera kune IBS-C, Linzess ndiyo FDA yakagamuchirwa kuitira kurapwa kwechirwere chinonzi idiopathic constipation (CIC) kuvanhu vakuru. MuEurope, mushonga unonzi Constella.
Amitiza (lubiprostone) zvakare FDA yakagamuchirwa kuitira kurapwa kweCIC pamwe neBS-C. Amitiza inokonzerwa nemapapiro mukati memubhedha wematumbo kusunungura mamwe mvura. Zvinosuruvarisa, kushungurudzika kunonyanya kushamisa uye kunofadza kushanda kweAmitiza.
Resolor / Resotran (prucalopride) imishonga inowanika muCanada neEurope. Resolor inoshanda pane yeurotransmitter serotonin mukati megomba uye, saka, mune rimwe boka remishonga seZelnorm , mushonga wakabviswa pamusika nemhaka yemigumisiro yakakomba. Zvisinei, Resolor yakagadzirirwa zvakasiyana kuitira kuti isadzivirire matambudziko iwayo akaoma. Kubva ikozvino, Resolor inogamuchirwa neEuropean Medicines Agency yekurapa kusagadzikana kwenguva refu kuvakadzi.
IBS Mishonga muChikamu chekuedza
Mishonga mitsva iri kuuya kumusika, uye zvimwe zvinogona kushandiswa mishonga zvinoshandiswa kuburikidza nekuchengeteka miedzo. Idzi ndidzo itsva dzinouya; zvose zviri mumatanho akasiyana-siyana ekuedzwa kuburikidza nekuchengeteka kwavo uye kubudirira. Kudzidza pamusoro pezvaunogona kuita kunogona kukubatsira kushanda nachiremba wako kuti ugadzire hurongwa hwehutano hweBS yako.
Asimadoline imishonga inosangana nemakiriniki ekuedzwa semushonga weBS-D. Mishonga yemishonga inonyanya kugadziriswa nzvimbo mukati memukati makuru; zvinotarisirwa kuti zvakadaro zvichachengetedza madhara kune zvishoma. Mumaedzo ekutanga, zvinoratidzika kuti mishonga inonyanya kukosha ndeyekuchera marwadzo emimba uye kusagadzikana.
Elobixibat imishonga ichiri kuongororwa semushonga weCIC. Inoshanda kuburikidza nekuderedza reabsorption ye bile acids kubva ku gallbladder, nokudaro kuwedzerwa kuwanda kweiyi acid inopinda mumuviri mako mukuru. Izvi zvinofungidzirwa kuti zvibatsire kukurumidzira kushandiswa kwenhau yefecal kuburikidza nekoloni. Ikozvino, sekusvika ikozvino, hapana kliniki yekutsvakurudza pane elobixibat yekubudirira paBS-C.
Plecanatide inoshanda zvakafanana neLinzess uye iye zvino iri kutarisana nemakiriniki ekuedzwa sekurapa kweBS-C neCIC.
Tenapanor imishonga yezvirwere zvepvo. Inoshanda kuburikidza nekuderedza kunwa kwe sodium mumugwagwa wezvokudya; kuwedzera kwehuwandu hwe sodium inofungidzirwa kuwedzera huwandu hwemvura mumatumbo makuru. Nokuda kweizvi, Tenapanor iye zvino ari kutarisana nemakiriniki ekuedzwa sekurapa kweBS-C.
Shoko Rinobva
Kunyange zvazvo iwe unogona kuona kune mhando dzakasiyana dzemishonga yeBS, vanhu vazhinji vane IBS vanoona kuti mishonga yavanoedza haina kukwana zvachose kubvisa zviratidzo zvavo. Mune zvimwe zviitiko, vanova nemigumisiro uye vanofanirwa kurega kutora mishonga. Nenguva isipi, mishonga haisi yega kurapa kweBS. Zvimwe zvaunogona kusanganisira zvinodarika-the-remedies remedy , dietary modifications , uye pfungwa dzepfungwa. Chengetedza mitsetse yekukurukurirana yakazaruka nachiremba wako kuti asvike pane chirongwa chakanakisisa chokurapa iwe.
Sources:
Lacy, B., Chey, W. & Lembo, A. "Zvitsva uye Kuwedzera Zvokurapa Zvimwe Zvinyorwa zveIrritable Bowel Syndrome" Gastroenterology & Hepatology 2015 11: 1-19.
Lazaraki, G., Chatzimavroudis, G. & Katsinelos, P. "Ichangobva kufambira mberi mukurapa kwemishonga yekutsamwisa kwemafupa echirwere" World Journal of Gastroenterology 2014 20: 8867-8885.
Peyton, L. & Greene, J. "Irritable Bowel Syndrome: Ikozvino uye Kuwedzera Kurapa Zvokudya" Pharmacy & Therapeutics 2014 39: 567-572, 578.
Jack J, Vanuytsel T, Corsetti M. "Mazuva Ano Maitiro Evanhu Vanokanganisa Bhuku Rekunyangarika: Zvinopfuura Kuita Mushonga." Kuderedza Zvirwere 2016; 34: 566-573.
Trinkley, K. & Nahata M. "Mishonga yekurapa yeIrritable Bowel Syndrome" Kubata 2014 89: 253-267.